Patents Assigned to AstraZeneca
  • NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
    Patent number: 9475773
    Abstract: A method for treating polycystic ovarian syndrome and related conditions with a compound (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: October 25, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Peter Stewart Gilmour, Tony Ho, Rahul Kakkar, Lorraine Webber
  • Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
    Patent number: 9468598
    Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: October 18, 2016
    Assignee: AstraZeneca AB
    Inventors: Rango Dietrich, Klaus Eistetter, Hartmut Ney
  • Crystal structures of SGLT2 inhibitors and processes for preparing same
    Patent number: 9453039
    Abstract: The present invention relates to physical crystal structures of a compound of the formula I: wherein R1, R2, R2a, R3 and R4 are as defined herein, especially pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: September 27, 2016
    Assignee: AstraZeneca AB
    Inventors: Jack Z. Gougoutas, Hildegard Lobinger, Srividya Ramakrishnan, Prashant P. Deshpande, Jeffrey T. Bien, Chiajen Lai, Chenchi Wang, Peter Riebel, John Anthony Grosso, Alexandra A. Nirschl, Janak Singh, John D. DiMarco
  • Hybrid polypeptides with selectable properties
    Patent number: 9453063
    Abstract: The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: September 27, 2016
    Assignees: Amylin Pharmaceuticals, LLC., AstraZeneca Pharmaceuticals LP
    Inventors: Odile Esther Levy, Michael R. Hanley, Carolyn M. Jodka, Diana Y. Lewis, Christopher J. Soares, Soumitra S. Ghosh, Lawrence J. D'Souza, David G. Parkes, Christine M. Mack
  • CHROMENONE DERIVATIVES
    Publication number: 20160272607
    Abstract: The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 22, 2016
    Applicant: AstraZeneca AB
    Inventors: Bernard Christophe BARLAAM, Sebastien Louis DEGORCE, Christine Marie, Paul LAMBERT-VAN DER BREMPT, Remy Robert MORGENTIN, Patrick PLE
  • Arginase inhibitors and methods of use thereof
    Patent number: 9447122
    Abstract: The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: September 20, 2016
    Assignee: AstraZeneca AB
    Inventors: Bruce Edward Tomczuk, Gary Lee Olson, Richard Scott Pottorf, Lijuan Jane Wang, Bhaskara Rao Nallaganchu, Yanqun Zhang
  • Methods for increasing forced expiratory volume in asthmatics using benralizumab
    Patent number: 9441046
    Abstract: Provided herein is are methods of increasing forced expiratory volume in one second (FEV1) in an asthma patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: September 13, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
  • Methods for improving asthma symptoms using benralizumab
    Patent number: 9441047
    Abstract: Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: September 13, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
  • Methods for reducing exacerbation rates of asthma using benralizumab
    Patent number: 9441037
    Abstract: Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: September 13, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
  • CARBOXYLIC ACID COMPOUNDS
    Publication number: 20160251319
    Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.
    Type: Application
    Filed: May 11, 2016
    Publication date: September 1, 2016
    Applicants: Sumitomo Dainippon Pharma Co., Ltd., Astrazeneca Aktiebolag
    Inventors: Seiji HORI, Futoshi HASEGAWA, Daisuke URABE, Hirotaka KUREBAYASHI
  • Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer
    Patent number: 9428503
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: August 30, 2016
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Kurt Gordon Pike
  • Chemical compounds
    Patent number: 9421213
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: August 23, 2016
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Johannes Wilhelmus Maria Nissink, Paul Turner
  • Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
    Patent number: 9402847
    Abstract: The present invention relates to a combination comprising (5)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof, hereafter “Compound (I)”, and a taxane. Taxanes include established cancer drugs such as docetaxel (Taxotere™) and paclitaxel (Taxol™). Such combinations may be useful in the treatment or prophylaxis of cancer. The invention also relates to a pharmaceutical composition comprising such Compound (I) and a taxane. The invention further relates to a method of treatment comprising the simultaneous, sequential or separate administration of Compound (I) and a taxane, to warm-blooded animal, such as man. The invention also relates to a kit comprising Compound (I) and a taxane, optionally with instructions for use.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: August 2, 2016
    Assignee: AstraZeneca AB
    Inventor: Barry Robert Davies
  • Benzoxazinone amides as mineralocorticoid receptor modulators
    Patent number: 9394291
    Abstract: Disclosed are certain derivatives of benzoxazinone amides of formula (I), or pharmaceutically acceptable salts thereof, that act as mineralocorticoid (MR) receptor modulators that may reduce oxidative stress in endothelium and hence improve vascular function, to methods for their potential therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: July 19, 2016
    Assignee: AstraZeneca AB
    Inventors: Gavin O'Mahony, Michael Kossenjans, Karl Edman, Johan Kajanus, Karl Anders Hogner, Philip Cornwall, Andrew Turner
  • Engineered polypeptides having enhanced duration of action with reduced immunogenicity
    Patent number: 9382304
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: July 5, 2016
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Manoj P. Samant, Abhinandini Sharma, Lala Mamedova, Esther Odile Levy, Caroline Ekblad
  • Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline
    Publication number: 20160185754
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Application
    Filed: July 22, 2015
    Publication date: June 30, 2016
    Applicant: ASTRAZENECA AB
    Inventors: Jorgen BLIXT, Michael David GOLDEN, Philip John HOGAN, David Michael Glanville MARTIN, Francis Joseph MONTGOMERY, Zakariya PATEL, John David PITTAM, George Joseph SEPENDA, Christopher John SQUIRE, Nicholas Cartwright Alexander WRIGHT
  • Carboxylic acid compounds
    Patent number: 9376398
    Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: June 28, 2016
    Assignees: Sumitomo Dainippon Pharma Co., LTD, Astrazeneca Aktiebolag
    Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
  • Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
    Patent number: 9375432
    Abstract: The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof: which possess inhibitory activity against activating mutant forms of EGFR, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of the compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: June 28, 2016
    Assignee: AstraZeneca AB
    Inventors: David Yunzhi Li, Jiabing Wang, Zhenfan Yang, Qingbei Zeng, Xiaolin Zhang
  • Chemical Compounds
    Publication number: 20160176906
    Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 23, 2016
    Applicant: AstraZeneca AB
    Inventors: Robert Bruce Diebold, Thomas Woodrow Gero, Paul Grover, Shan Huang, Stephanos Ioannidis, Claude Afona Ogoe, Jamal Carlos Saeh, Jeffrey Gilbert VARNES
  • Azaindole derivatives
    Patent number: 9371321
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating immunological disorders, cardiovascular disease, cancer, and other diseases, disorders or conditions associated with PI3K?.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: June 21, 2016
    Assignee: AstraZeneca AB
    Inventors: Edcon Chang, Christopher Smith, Xiaolun Wang, Michael B. Wallace